CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Pancreatic Enzyme Testing for Acute Pancreatitis

Describes coverage criteria for measurement of pancreatic enzyme biomarkers (serum lipase, serum amylase, urinary amylase, trypsin/trypsinogen/TAP, and inflammatory biomarkers) for diagnosis, prognosis, severity assessment, and monitoring of acute and chronic pancreatitis for Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyPancreatic Enzyme Testing for Acute Pancreatitis

Policy CodePolicy N/A

Change TypeN/A

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionOrder serum lipase (preferred) OR amylase for initial diagnosis of acute pancreatitis; avoid ordering both tests together.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Coveredcoverage position for initial diagnosis

Not covereddouble-testing rule

Not coveredurinary amylase stance

2023-07-01effective date

7CPT/HCPCS listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Pancreatic Enzyme and Biomarker Testing

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in Section VII of this policy document.

ALL of the following

Measurement of either serum lipase (preferred) OR amylase concentration for the initial diagnosis of acute pancreatitis meets coverage criteria in all patients presenting with signs and symptoms of acute pancreatitis (see Note 1).
Not covered situations
- Measurement of either serum lipase (preferred) OR amylase concentration as part of an ongoing assessment of therapy for acute pancreatitis.
- Measurement for determining the prognosis of pancreatitis.
- Measurement for determining the severity or progression of pancreatitis.
- Measurement performed more than once per visit.
- Measurement for the diagnosis, prognosis, or severity of chronic pancreatitis.
- Measurement as part of ongoing assessment or therapy of chronic pancreatitis.
- Measurement in asymptomatic nonpregnant individuals during general exam without abnormal findings.
Measurement of both amylase AND serum lipase for diagnosis or assessment of acute pancreatitis does not meet coverage criteria.
Measurement of serum or urine trypsin/trypsinogen/TAP (trypsinogen activation peptide) for diagnosis or assessment of acute pancreatitis does not meet coverage criteria.
Biomarkers considered not meeting coverage criteria due to insufficient evidence
- C-reactive protein (CRP) for diagnosis or determination of severity of acute pancreatitis does not meet coverage criteria.
- Interleukin-6 (IL-6) for diagnosis or determination of severity of acute pancreatitis does not meet coverage criteria.
- Interleukin-8 (IL-8) for diagnosis or determination of severity of acute pancreatitis does not meet coverage criteria.
- Procalcitonin for diagnosis or determination of severity of acute pancreatitis does not meet coverage criteria.
Measurement of urinary amylase concentration for the initial diagnosis of acute pancreatitis does not meet coverage criteria in all patients presenting with signs and symptoms of acute pancreatitis (see Note 1).

COVERAGE CRITERIA — stance on biochemical tests for diagnosis and monitoring of acute pancreatitis with supporting evidence/guidelines

Current guideline and evidence-based stance on biochemical tests for diagnosis and monitoring of acute pancreatitis:

ALL of the following

Major society guidelines endorse using the revised Atlanta classification: diagnosis requires ≥2 of the following — characteristic abdominal pain, serum amylase or lipase >3× upper limit of normal, or imaging consistent with pancreatitis.
Serum lipase is preferred over amylase due to higher sensitivity and a longer diagnostic window; lipase levels remain elevated longer, improving detection when presentation or testing is delayed.
Either serum amylase or serum lipase should be tested within 48 hours of admission; lipase is preferred when available.
Routine or serial daily measurement of amylase or lipase after diagnosis has limited value for assessing clinical progress and is not recommended for monitoring prognosis or severity in the absence of new/worsening symptoms.

coverage criteria and guidance — summarized guidance from professional societies and reimbursement policy statements

Summarized guidance from professional societies and reimbursement policy statements relevant to ordering and reimbursement:

ALL of the following

Do not order amylase if serum lipase testing is available for diagnosis and management of acute pancreatitis; amylase may be considered only when lipase is unavailable as a stat test and clinical presentation warrants urgent testing.
Amylase is nonspecific and can be elevated in many non-pancreatic conditions; avoid routine amylase testing for pancreatitis when lipase is available.
Discourage co-ordering of amylase and lipase as a default order set; removing amylase from common order sets reduces unnecessary testing and costs.
Repeat pancreatic enzyme testing should be limited to situations with new or persisting signs of pancreatic or peripancreatic inflammation, suspected ductal obstruction, or development of complications such as pseudocyst.

Regulatory, test classification, and coding notes — FDA/LDT/classification and coverage-related statements

Regulatory status, test classification, and coding notes relevant to coverage and billing:

ALL of the following

FDA has approved multiple serum assays for total and pancreatic amylase and for serum lipase; these are cleared in vitro diagnostics when marketed as such.
Trypsin immunostaining, trypsinogen-2 dipstick, and TAP assays are typically laboratory-developed tests (LDTs) and are regulated under CLIA as high-complexity tests; they have not received FDA clearance/approval for these specific LDT implementations.
IL-6 and IL-8 assays are commonly ELISA-based and are often offered as LDTs or as part of cytokine panels; availability and validation vary by laboratory.
CRP and procalcitonin assays: multiple FDA-cleared assays exist for CRP and for procalcitonin (eg, Diazyme PCT assay, Atellica IM BRAHMS PCT device), reflecting cleared options for these biomarkers when clinically indicated.

Applicable Codes, Coding Notes, and Thresholds

applicable CPT/HCPCSmixed

No codes listed

coding notesmixed

No explicit CPT/HCPCS/ICD codes present in this excerpt

FDA-cleared assaysmixed

	FDA has approved multiple tests for serum total and pancreatic amylase
	FDA has approved multiple tests for serum lipase

Applicable procedure codesCPT

82150	Amylase
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83529	Interleukin-6 (IL-6)
83690	Lipase
84145	Procalcitonin (PCT)
86140	C-reactive protein

inv-09: diagnostic threshold (general guideline)

Diagnostic threshold (general guideline)Serum lipase or amylase ≥ 3× upper limit of normal (URL) is diagnostic when combined with clinical criteria (pain or imaging)

Clinical requirementDiagnosis requires at least 2 of 3 Atlanta criteria: characteristic abdominal pain, enzyme elevation ≥3× URL, or characteristic imaging findings

Source guideline referenceAtlanta classification (revised 2012) commonly used by major societies

inv-10: diagnostic enzyme threshold — >3× upper limit of normal (Atlanta classification)

Atlanta classification threshold>3× upper limit of normal (URL) for serum amylase or lipase per Atlanta criteria

Provider Actions, Ordering and Billing Guidance

Note

Use of inflammatory markers for severity assessment

Use inflammatory markers (for example, CRP, procalcitonin, IL-6, LDH, serum cholinesterase) only when needed for prognostic assessment or as adjuncts to clinical and imaging evaluation. These markers have shown prognostic value for severity and mortality in acute pancreatitis but are not routinely covered for ongoing monitoring or as standalone diagnostic tests. Prefer imaging (CT) and validated clinical severity scores (e.g., APACHE-II) over routine serial inflammatory-marker measurement for severity assessment. If inflammatory markers are used, document the specific clinical question (prognosis, suspected necrosis, or organ failure) and how the result will change management to support medical necessity.

CRP: may help detect pancreatic necrosis (maximal at 48–72 hours) but sensitivity/specificity limitations — not for routine serial monitoring.
Procalcitonin, IL-6, IL-8, LDH: have prognostic value in studies but limited routine coverage; consider when results will impact escalation of care.
Serum cholinesterase: associated with severity/mortality in cohort studies but not a routine covered test for monitoring.
Document clinical indication (e.g., suspected infected necrosis, unexplained deterioration, organ failure) to justify testing.

Definitions, Test Characteristics, and Background

inv-19: Acute pancreatitis (AP) definition and diagnostic criteria overview

Definition of APAcute pancreatitis is inflammation of the pancreatic tissue; diagnosis requires at least 2 of 3 features: characteristic abdominal pain, serum lipase or amylase ≥3× URL, or characteristic imaging findings (CECT/MRI/ultrasound)

Temporal phasesAP may be characterized by early or late phases with varied severity

Consensus originDiagnostic criteria derive from the Atlanta classification (1992, revised 2012)

inv-20: Amylase / Lipase — timing, elevation duration, and preference for lipase

Timing of riseLipase and amylase increase within ~3–6 hours after pancreatic injury

Duration of elevation

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyPancreatic Enzyme Testing for Acute Pancreatitis

Policy CodePolicy N/A

Change TypeN/A

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionOrder serum lipase (preferred) OR amylase for initial diagnosis of acute pancreatitis; avoid ordering both tests together.

SourceLink

On This Page

Testing both amylase and lipase simultaneously is discouraged: it increases cost with only marginal diagnostic benefit over lipase alone.

Some biomarkers (CRP, IL-6, IL-8, procalcitonin, trypsinogen/TAP) have been evaluated for prognosis/severity assessment, but available evidence does not support their routine use for diagnosis or standard assessment of severity; recommendations vary and many remain not routinely endorsed for initial diagnosis.

See professional society guidance summaries (IAP/APA, AGA, ACG, ABIM/ASCP/Choosing Wisely) for specifics on thresholds (commonly ≥3× ULN) and context for use of CRP for severity assessment (eg, CRP >150 mg/L at 48 hours may be used as an adjunct).

Some society positions note threshold values (commonly ≥3× upper limit of normal) for diagnostic consideration; however, some groups advise against rigid reliance on arbitrary multiples (eg, UK Working Party commentary).

Applicable CPT codes include: 82150 (amylase), 83690 (lipase), 84145 (procalcitonin), 86140 (C-reactive protein), 83529 (interleukin-6), and immunoassay codes 83519/83520 for quantitative immunoassays; laboratories should bill using the appropriate CPT that reflects the specific assay performed and its regulatory status.

Society endorsementIAP/APA and AGA/ACG cite >3× URL as diagnostic cut-off in guideline statements

ApplicationUsed as one of two required findings (with pain or imaging) to establish diagnosis

inv-11: diagnostic threshold — commonly ≥3× URL; some societies vary (2–4×) or use time-based interpretation

Common practiceMost professional groups commonly use a ≥3× URL threshold for serum pancreatic enzymes

VariabilitySome societies or working groups interpret thresholds relative to time since pain onset or allow ranges of ~2–4× URL rather than strict cut-offs

Time-based considerationUK Working Party and other guidelines caution against reliance on arbitrary fixed multiples and recommend interpreting enzyme values in clinical context and timing

Serum lipase remains elevated ~1–2 weeks (commonly 8–14 days); amylase returns to normal much sooner (half-life ~12 hours)

Test preferenceLipase is preferred due to greater sensitivity, specificity, and longer diagnostic window

inv-21: Diagnosis of acute pancreatitis — Atlanta/major society criteria summary

Atlanta/major society criteriaDiagnosis requires ≥2 of: characteristic abdominal pain; biochemical evidence (amylase or lipase >3× URL); or radiographic evidence of pancreatitis

Society consensusIAP/APA, AGA, ACG and others endorse the two-of-three diagnostic framework

Practical noteEnzyme testing should be interpreted alongside timing of symptom onset and imaging; do not rely solely on serial enzyme measurements for prognosis

inv-22: Urine trypsinogen-2 dipstick (UTDT) — point-of-care urine test characteristics and regulatory status

Test descriptionUrine trypsinogen-2 dipstick is a point-of-care urine test detecting urinary trypsinogen-2 (eg, Actim Pancreatitis test strip)

Performance characteristicsReported sensitivity/specificity vary by study (examples: specificity 85% for severe AP; sensitivity reported 67–94% across studies)

Regulatory statusAs of 2020 the FDA has not approved the trypsinogen-2 dipstick for detection/diagnosis of AP in the U.S.; clinical trials ongoing

inv-23: serum lipase — preferred test

Preferred analyteSerum lipase is the preferred test for initial diagnosis of acute pancreatitis

Diagnostic advantageLipase has higher sensitivity and specificity than amylase and a wider diagnostic window, making it more useful when presentation is delayed

Clinical guidanceDo not order amylase if lipase is available; consider amylase only if lipase is not available as a stat test

inv-24: serum amylase — less specific; consider when lipase not available

Specificity limitationsAmylase is less specific than lipase and can be elevated from nonpancreatic causes (eg, salivary disease, intestinal pathology, macroamylasemia)

Timing constraintAmylase rises early but has a short half-life (~12 hours) and often normalizes quickly, reducing diagnostic value if testing is delayed

Use caseConsider measuring amylase only when serum lipase is not available as a stat test; routine dual-ordering with lipase is discouraged

inv-25: Laboratory developed test (LDT) — definition and regulatory note

DefinitionLaboratory-developed tests (LDTs) are assays developed, validated and performed by individual laboratories

Regulatory noteLDTs are regulated by CMS as high-complexity tests under CLIA '88; FDA approval/clearance is not required for LDT clinical use

Examples in policyTrypsin immunostaining, trypsinogen-2 dipstick, and TAP serum tests are characterized as LDTs in this policy

inv-26: C-reactive protein (CRP) assays — FDA approvals and assay types

Regulatory approvalsFDA has approved multiple assays for conventional CRP, high-sensitivity CRP (hsCRP), and cardiac CRP (cCRP); FDA issued assessment guidance for CRP in 2005

Clinical timingCRP peaks 48–72 hours after symptom onset and is used for severity/necrosis assessment rather than initial diagnosis

Role in APCRP is widely studied for prognostication but is not practical for early diagnosis due to delayed accuracy

inv-27: Procalcitonin (PCT) assay — device approvals and notes

Device approvalsSpecific procalcitonin assays/devices have received FDA clearance/approval (eg, Diazyme PCT assay in 2017; Atellica IM BRAHMS PCT device in 2018)

Prognostic useProcalcitonin has been studied for early assessment of pancreatic infection and prognosis in severe AP but is not recommended as a sole triage marker

Evidence sourcesProspective and multicenter studies cited for PCT utility in assessing infection and prognosis

inv-28: References / Guidelines — bibliographic references and guideline sources

Guideline and literature sourcesKey references include Atlanta classification papers, ACG 2013 guideline, AGA 2018 guideline, Cochrane review (Rompianesi et al. 2017), and multiple primary studies and reviews

Systematic reviewsCochrane review on serum amylase/lipase and urinary trypsinogen/amylase for AP diagnosis is cited

Additional studiesSelected studies on urinary trypsinogen/TAP, CRP, procalcitonin, and enzyme behavior are listed (eg, Neoptolemos 2000; Yasuda 2019; Tenner et al. 2013)